Clinic study for early blood or bone marrow warning signs
Part of Blood & lymphatic, Cancer, Genetic & congenital clinical trials.
This study follows people who may have early, unclear blood count problems or certain genetic/immune patterns that can later lead to bone marrow failure or blood cancers. It may help doctors better understand risks over time and guide earlier care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older
- You have persistent low blood counts with no clear cause (idiopathic cytopenias)
- OR you have a blood pattern called CHIP/CHIP syndrome, like VEXAS, that may raise risk
- OR you have related conditions such as CCUS, low-risk MDS, or bone marrow failure linked to higher cancer risk
- OR you have an inherited genetic syndrome that can raise cancer risk (for example, GATA2 or RUNX1)
- A close family member also has one of these conditions, or you are considered high risk/suspected to develop one
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows adults who have certain blood-cell DNA changes (CHIP or CCUS) to learn how their condition may progress over time. It mainly looks at natural history—what happens in the blood without giving an active treatment.
This trial tests an early treatment for people with a condition called high-risk CCUS, where low blood counts and gene changes raise the risk of developing blood cancer. The goal is to see if intervening early can prevent or delay progression to leukemia or MDS.
This study looks at how certain age-related changes in blood cells, called clonal hematopoiesis, affect inflammation and health. It aims to understand why some people with these changes develop heart problems or blood disorders, which could guide future prevention.
This Phase 2 study tests canakinumab to help stop high-risk clonal cytopenias of unknown significance (CCUS) from progressing into a blood cancer. If you have persistent low blood counts and specific genetic features, this treatment may lower the chance of progression.
This study looks at how CAR-T therapy affects blood cell counts (cytopenia) in people with multiple myeloma or certain lymphomas/leukemias. You will provide biological samples to help researchers understand these effects.
This study looks for early signs of blood cancers in people who have them or are at higher risk, like family members or older adults. It aims to find cancer sooner, which may lead to better outcomes.
Hear when a new Myeloid Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.